Navigation Links
S*BIO to Initiate Global Phase 3 Clinical Trials of its Novel JAK2 Inhibitor Pacritinib for Treatment of Myelofibrosis (MF)
Date:10/25/2011

SINGAPORE, Oct. 25, 2011 /PRNewswire/ -- S*BIO Pte Ltd today announced plans to initiate a global Phase 3 clinical program of its novel JAK2 inhibitor pacritinib (SB1518), in the first half of 2012 to further demonstrate its activity and tolerability for the treatment of myelofibrosis (MF). The company is actively exploring partnering opportunities for the advancement of its leading JAK2 program.

"Data from Phase 1 and 2 clinical studies have demonstrated that pacritinib is well tolerated and active in the treatment of myelofibrosis, an orphan disease with a high unmet medical need," said Tamar Howson, interim CEO and board member of S*BIO. "We are moving forward with an aggressive and focused development plan with global Phase 3 trials for pacritinib to further demonstrate its clinical benefits in MF patients and to maximise the value of our JAK2 program. We are currently in the process of identifying a suitable partner for the Phase 3 studies and pacritinib's subsequent commercialization."

The primary objective of the double-blind, placebo-controlled Phase 3 studies is to compare the efficacy of pacritinib versus placebo in achieving clinically significant reduction in spleen size in MF patients with splenomegaly. Secondary outcomes of both studies include patient-reported change in the most bothersome symptom identified at baseline, duration of response, as well as overall survival. The trials will enrol up to 500 MF patients.

In Phase 2 studies, treatment with pacritinib resulted in sustained reduction in MF-associated splenomegaly with no evidence of myelosuppression and no exacerbation of cytopenias. Pacritinib is a small molecule JAK2-selective kinase inhibitor that demonstrated high potency in preclinical models against both the wild type JAK2 kinase and the JAK2 kinase with the V617F mutation. The V617F mutation is found in high frequency in myeloproliferative disorders such as MF. More than 50% of patients with MF possess the JAK2 mutation.

About S*BIO Pte LtdS*BIO is a privately-held biotech company focused on the clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs including kinases and histone deacetylases (HDAC). Pacritinib, or SB1518, S*BIO's potent and orally-active JAK2 inhibitor, entered the clinic in 2008 and has completed Phase 2 trials for MF.  It has received orphan drug designation from the U.S. and the E.U. regulatory authorities. S*BIO's lead HDAC inhibitor, pracinostat (SB939), is currently in Phase 2 trials. S*BIO's SB1317, a novel multikinase inhibitor, is in Phase 1 trials and under a worldwide exclusive license with Tragara Pharmaceuticals, Inc. for its development and commercialization.

S*BIO has strong links with a network of medical oncologists in Asia Pacific and its investors include Bio*One Capital a subsidiary of EDBI (EDB Investments), Aravis Ventures, Mitsui Ventures, Novartis Bioventures and other international funds. More information about S*BIO can be found at www.sbio.com.S*BIO Pte Ltd:Russo PartnersTamar Howson

Tony Russo +1 212-845-4251Interim CEO & Board Member

Tony.Russo@russopartnersllc.comtamarhowson@me.com

Andreas Marathovouniotis +1 212-845-4235Andreas.Marathis@russopartnersllc.com
'/>"/>

SOURCE S*BIO Pte Ltd
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Additional Data From Multiple Phase 1 and 2 Studies of S*BIOs Novel JAK2 Inhibitor SB1518 Demonstrate Safety and Efficacy for Treatment of Symptomatic Myelofibrosis (MF)
2. S*BIO Restructures Agreement With Onyx for JAK2 Inhibitor Program
3. S*BIOs Novel Dual mTOR/PI3 Kinase Inhibitor SB2343 Demonstrates Excellent PK/PD Properties Leading to Significant Anti-Tumor Efficacy in Xenograft Models
4. S*BIOs JAK2 Inhibitor SB1518 Granted Orphan Drug Designation by European Commission (EC) for the Treatment of Myelofibrosis (MF)
5. S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis
6. S*BIO Initiates U.S. Phase I Clinical Trials of Oral JAK2 Inhibitor SB1518 for the Treatment of Hematological Malignancies
7. S*BIO to Develop New JAK-2 Inhibitor for Treatment of Myeloproliferative Disorders and Hematological Malignancies
8. Elusys Initiates Third Clinical Safety Study of Anthim, a New Anthrax Treatment; Company Successfully Completes Manufacturing at Commercial Scale
9. CryoLife Initiates Enrollment in U.S. Clinical Trial for BioFoam®
10. CareFusion Initiates Class I Recall of EnVe Ventilators
11. Takeda Initiates Phase 3 Clinical Trial Program in the United States, Latin America, and Europe for Investigational Type 2 Diabetes Therapy TAK-875
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... 3, 2016 BioNovus Innovations LLC and ... Advancing Medical Innovation (IAMI) today announced a new ... and medical devices. An agreement between ... to license, develop and commercialize medical innovations advanced ... "This partnership represents a significant advance in our ...
(Date:5/3/2016)...  As a teenager, an active and athletic ... his heart. He continued enjoying sports and recreation throughout ... heart was giving out and he was a few ... the Mesa, Arizona resident received ... heart transplant, the SynCardia TAH-t is the only approved ...
(Date:5/3/2016)... ORANGE COUNTY, Calif. , May 3, 2016  While you may be familiar with watching ... 4K resolution , also known as ultra-high-definition or 8MP in the Medical Industry.  Ampronix  is ... class manufacturer of innovative technology. Photo - http://photos.prnewswire.com/prnh/20160502/362730 ... ... ...
Breaking Medicine Technology:
(Date:5/6/2016)... ... 2016 , ... US Sports Camps has collaborated with State Rugby Organization (SRO), ... this summer. Employing world-class rugby figures, including former Team USA players and college coaches, ... key fundamentals, match play, fitness and more. , “US Sports Camps is honored to ...
(Date:5/6/2016)... FL (PRWEB) , ... May 06, 2016 , ... ... will feature AsedaSciences® in an upcoming episode, airing third quarter 2016, via Discovery ... the vision of becoming a leader in optimized drug discovery through innovative cellular ...
(Date:5/6/2016)... (PRWEB) , ... May 06, 2016 , ... Online HR/benefits ... and are changing the game for traditional brokers and health plans. “ The Rapid ... May 17 webinar from Atlantic Information Services, Inc. (AIS), will offer an accurate picture ...
(Date:5/6/2016)... ... 06, 2016 , ... Canadian author Mark Black is a speaker, author, and life ... around the world … with the help of his publisher Strategic Book Group and its ... in a hospital bed waiting for a miracle: He needed a heart and double-lung transplant. ...
(Date:5/6/2016)... ... 06, 2016 , ... Multiple award winning plumbing company in San ... years. Maintaining core values of exceptional customer service, quality work at reasonable rates, and ... name in San Diego plumbing, and other services including heating & air conditioning and ...
Breaking Medicine News(10 mins):